WebDoctor Encyclopedia

Central nervous system Childhood

Astroblastoma, MN1-altered

Astroblastoma, MN1-altered is a rare brain tumour defined by a change in the MN1 gene. It mostly affects children, teenagers and young women and usually grows in the cerebral hemispheres. Complete surgical removal gives the best chance of long-term control.

Medically reviewed Last reviewed October 20, 2026

What is astroblastoma, MN1-altered?

Astroblastoma is a rare brain tumour that usually grows in the cerebral hemispheres, the large upper parts of the brain. It most often affects children, teenagers and young women. The tumour was first described almost a century ago, but for decades doctors disagreed about what kind of cell it came from and how it should be classified (Lehman, 2023).

Under the microscope, astroblastoma cells are arranged around blood vessels like the spokes of a wheel, forming so-called astroblastic pseudorosettes. Many tumours with this appearance, especially in young people, carry a rearrangement of a gene called MN1 on chromosome 22. The MN1 gene is often joined to a partner gene on the X chromosome, most commonly BEND2, creating an MN1::BEND2 fusion.

The World Health Organization (WHO) classification of brain tumours now defines astroblastoma by this genetic change, using the name “astroblastoma, MN1-altered”. Tumours that look like astroblastoma but lack an MN1 change, particularly in adults, often turn out to be other tumour types when tested more fully (Boisseau et al., 2019).

Most MN1-altered astroblastomas are well defined and can often be removed completely by surgery. Many patients do well after surgery, but some tumours come back, so long-term follow-up with MRI scans is important. Radiotherapy and chemotherapy are used for tumours that recur or cannot be fully removed.

1. Key facts at a glance

Feature Details
Type of tumour Circumscribed glial tumour defined by MN1 alteration
Where it grows Cerebral hemispheres, usually near the brain surface
Who is affected Mainly children, teenagers and young adults; strong female predominance
Genetic hallmark MN1 rearrangement, often MN1::BEND2 fusion
Main symptoms Headaches, seizures, nausea, weakness
Scan appearance Well-defined, mixed cystic and solid enhancing mass with a “bubbly” look
Main treatment Surgical removal; radiotherapy for some
WHO grade Not yet formally assigned
Outlook Often good after complete removal; recurrence possible

2. Types

Tumours with astroblastoma-like appearance

Tumour Key genetic feature Usual patient Behaviour
Astroblastoma, MN1-altered MN1 rearrangement (often with BEND2) Girls and young women Often favourable after removal
Pleomorphic xanthoastrocytoma-like tumours BRAF mutation Adults and young people Often favourable
High-grade glioma-like tumours Alterations typical of glioblastoma or diffuse midline glioma Adults Aggressive
Ependymoma Various fusions Children and adults Variable

In a study of 15 adolescents and adults with tumours that had been diagnosed as astroblastoma, only one had an MN1 fusion. Most were reclassified as either pleomorphic xanthoastrocytoma-like or high-grade glioma-like tumours, and the high-grade glioma-like group had significantly shorter survival (Boisseau et al., 2019).

Low-grade and high-grade features

Feature Low-grade appearance High-grade (anaplastic) appearance
Cell division Infrequent Frequent
Dead tissue Absent May be present
Proliferation index Low Higher
Behaviour May still recur Not always aggressive if fully removed

Microscopic grade does not always predict how the tumour will behave. Some low-grade tumours with marked swelling around them recur early, while some high-grade tumours that are well defined do better than expected (Janz and Buhl, 2014).

Some researchers describe tumours with the MN1::BEND2 fusion as an early ependymal tumour, separate from classical astroblastoma. These occur mostly in young girls and have a very good prognosis with surgery (Lehman, 2023). Classification is still evolving, and your pathologist will explain how your tumour has been labelled.

3. Causes and risk factors

The cause of astroblastoma is unknown.

Factor Notes
Female sex Strongly over-represented; female-to-male ratio about 8:1 in one review
Young age Median age about 14 years in a large review
MN1 rearrangement Arises in the tumour only; not inherited
X chromosome changes Frequent losses on the X chromosome in tumour cells (Hirose et al., 2018)
Lifestyle or environment No known link
Inherited syndromes None established

Why the tumour affects girls and women so much more often is not understood. The involvement of the X chromosome in the gene fusion may be part of the explanation.

4. How does it look

On scans

A systematic review of 127 cases described the typical imaging features (Cunningham et al., 2016).

Feature How often reported
Above the tentorium (cerebral hemispheres) 96%
Near the surface of the brain 72%
Well-defined borders 96%
Mixed cystic and solid 93%
Contrast enhancement 99%
Calcification on CT 73%
Swelling around the tumour 80%, usually mild
Restricted diffusion on MRI In all cases where reported

The solid parts often look dark on both T1 and T2 MRI sequences, and the tumour may have a “bubbly” appearance. Superficial tumours can gradually thin the overlying skull bone.

Under the microscope

Feature Description
Pseudorosettes Tumour cells with broad processes arranged around blood vessels
Blood vessels Thickened, glassy (hyalinised) walls
Border Sharp separation from surrounding brain
Patterns Trabecular, pseudopapillary or solid areas
Stains GFAP, Olig2, S-100 and EMA variably positive; IDH1 R132H negative

Genetic testing

Test Purpose
MN1 break-apart FISH Detects MN1 rearrangement
RNA sequencing Identifies the fusion partner, such as BEND2
DNA methylation profiling Classifies the tumour among related types
BRAF and other gene tests Identify look-alike tumours

5. Symptoms

Symptoms depend on the size and position of the tumour.

Common symptoms

  • Headaches, often worse in the morning
  • Seizures, sometimes affecting one part of the body
  • Nausea and vomiting
  • Dizziness

Less common symptoms

Symptom Possible cause
Weakness or numbness on one side Pressure on movement or sensory areas
Speech or language difficulties Tumour in the dominant hemisphere
Visual problems Tumour near visual pathways or raised pressure
Behaviour or personality change Frontal lobe tumours
Drowsiness High pressure in the head

When to seek urgent help

Seek urgent medical help for a first seizure, a seizure lasting more than five minutes, severe headache with vomiting, sudden weakness or drowsiness.

6. Diagnosis

Test Purpose
MRI of the brain with contrast Main imaging test
CT scan Shows calcification and bone changes
MRI of the spine Considered if spread is suspected
Surgery or biopsy Provides tissue for diagnosis
Neuropathology with molecular testing Confirms MN1 alteration and excludes look-alike tumours
EEG If seizures are present
Neuropsychology assessment Baseline memory and thinking skills

Because tumours with this appearance include several different diseases, experts recommend thorough molecular testing, especially in adults (Boisseau et al., 2019).

7. Treatment

There are no clinical trials specific to this tumour. Treatment is based on case series, reviews and the experience of specialist neuro-oncology teams.

Surgery

Aspect Details
Aim Complete (gross total) removal where safe
Why it is often possible The tumour is usually well defined and near the surface
Monitoring during surgery Brain mapping may be used near important areas
Repeat surgery Often used for local recurrence

Radiotherapy

Situation Approach
Complete removal of a low-risk tumour Often observation with MRI scans
Incomplete removal Focal radiotherapy considered
Recurrence Focal radiotherapy, often after further surgery
Low-grade tumour with marked swelling Combined surgery and radiotherapy suggested in one review (Janz and Buhl, 2014)

In children, teams aim to limit radiotherapy where possible, because of its long-term effects on the developing brain.

Chemotherapy

Chemotherapy has an uncertain role. It is generally reserved for tumours that recur repeatedly or cannot be controlled with surgery and radiotherapy, often within a clinical trial or after specialist review.

Treatment by situation

Situation Typical approach
MN1-altered, fully removed MRI surveillance
MN1-altered, residual tumour Further surgery or focal radiotherapy
Recurrence Surgery, radiotherapy, sometimes chemotherapy
Astroblastoma-like tumour without MN1 alteration Treated according to the tumour type found on molecular testing

Recovery after surgery

Period What to expect
First days Close monitoring; headache and tiredness are common
1-2 weeks Most people go home; wound care and gentle activity
2-4 weeks Results of molecular tests and a decision about further treatment
1-3 months Gradual return to school or work, often part-time at first
Longer term Recovery of strength, speech or concentration may continue for months

Seizure management

Measure Details
Anti-seizure medicines Started if seizures occur
Review after surgery Many people can reduce or stop medicines over time
Safety advice Driving, swimming and bathing precautions

Side effects

Treatment Possible side effects
Brain surgery Temporary weakness, speech problems, seizures, infection
Radiotherapy Tiredness, hair loss, memory and learning effects, hormone problems in children
Chemotherapy Low blood counts, nausea, infection risk
Anti-seizure medicines Tiredness, mood changes, dizziness

8. Outlook (prognosis)

Factor Effect
MN1 alteration confirmed Generally associated with a favourable course
Complete removal Better long-term control
High-grade glioma-like molecular profile Much poorer outlook; a different disease
Recurrence Can often be treated again

In a series of eight astroblastomas, six of the seven patients with follow-up data survived without recurrence, while one had several recurrences (Hirose et al., 2018). Tumours with the MN1::BEND2 fusion in young girls are reported to have a very good prognosis with surgery (Lehman, 2023).

Some tumours recur years later, sometimes as nodules along the brain lining, and may show more aggressive features over time (Janz and Buhl, 2014).

9. Follow-up

Time Typical checks
After surgery MRI within days to confirm the extent of removal
First 2 years MRI every 3-6 months
Years 3-5 MRI every 6-12 months
After 5 years Yearly or less often, as advised
Children Growth, hormone, learning and school support

10. Living with astroblastoma

  • Take anti-seizure medicines as prescribed and keep a seizure diary
  • Follow driving rules after seizures or brain surgery
  • Ask for school or workplace adjustments during recovery
  • Rest and pace activities; fatigue is common
  • Ask about neuropsychology support for memory or concentration
  • Keep follow-up scans, even after years without problems
  • Tell teachers and employers about seizure first aid if seizures are a risk
  • Seek support from brain tumour and children’s cancer charities

11. Frequently asked questions

Question Answer
Is astroblastoma cancer? It is a primary brain tumour; its behaviour ranges from slow-growing to more aggressive
Why is the MN1 test important? It confirms the diagnosis and separates it from look-alike tumours with different outlooks
Why does it affect girls more? The reason is unknown; X chromosome changes may be involved
Is it inherited? No; brothers and sisters do not need screening
How long will recovery take? Often weeks to a few months, depending on the tumour’s position
Will I need radiotherapy? Not always; often only if removal is incomplete or the tumour recurs
Can it come back? Yes, sometimes years later, so scans continue long term
Can I play sport after treatment? Usually, once your team agrees; contact sports may need a longer wait
Will it affect fertility? Surgery does not; ask your team about possible effects of radiotherapy or chemotherapy
Can I live a normal life? Many people return to school, work and usual activities

12. Questions to ask your care team

  • Has an MN1 alteration been confirmed, and what is the partner gene?
  • Was the tumour completely removed?
  • Do I need radiotherapy now, or only if it returns?
  • How will we manage seizures?
  • How often will I have MRI scans?
  • What support is available for school, work and memory?
  • Should my samples be reviewed at a reference centre for rare brain tumours?
  • Is there a registry or study collecting information on this tumour?

Resources

  1. Boisseau, W. et al. (2019) ‘Molecular profiling reclassifies adult astroblastoma into known and clinically distinct tumor entities with frequent mitogen-activated protein kinase pathway alterations’, The Oncologist, 24(12), pp. 1584-1592.
  2. Cunningham, D.A. et al. (2016) ‘Neuroradiologic characteristics of astroblastoma and systematic review of the literature: 2 new cases and 125 cases reported in 59 publications’, Pediatric Radiology, 46(9), pp. 1301-1308.
  3. Hirose, T. et al. (2018) ‘Astroblastoma: a distinct tumor entity characterized by alterations of the X chromosome and MN1 rearrangement’, Brain Pathology, 28(5), pp. 684-694.
  4. Janz, C. and Buhl, R. (2014) ‘Astroblastoma: report of two cases with unexpected clinical behavior and review of the literature’, Clinical Neurology and Neurosurgery, 125, pp. 114-124.
  5. Lehman, N.L. (2023) ‘Early ependymal tumor with MN1-BEND2 fusion: a mostly cerebral tumor of female children with a good prognosis that is distinct from classical astroblastoma’, Journal of Neuro-Oncology, 161(3), pp. 425-439.
  6. National Cancer Institute (2026) Adult Central Nervous System Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.